Login to Your Account



Clinic Roundup


Thursday, March 10, 2011
• ERYtech Pharma Inc., of Lyon, France, completed enrollment and safety follow-up in a Phase II trial of GRASPA (encapsulated L-asparaginase in red blood cells) in first-line acute lymphoblastic leukemia in patients older than 55. The firm anticipates reporting data from the 30-patient study in the third quarter.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription